Nautilus Biotechnology, Inc. (NAUT)
NASDAQ: NAUT · Real-Time Price · USD
2.410
+0.070 (2.99%)
Nov 21, 2024, 2:38 PM EST - Market open

Company Description

Nautilus Biotechnology, Inc., a development stage life sciences company, engages in creating a platform technology for quantifying and unlocking the complexity of the proteome.

The company develops Nautilus Platform, a proteomics platform that includes end-to-end solution comprised of instruments, consumables, and software analysis.

It also offers proteome analysis system, a high-resolution optical imaging system for integrated fluidics and liquid handling sub-system.

In addition, the company provides sample preparation, flow cells, multi-affinity probe reagents, and instrument buffers system to perform multi-cycle analysis runs.

Nautilus Biotechnology, Inc. was incorporated in 2016 and is headquartered in Seattle, Washington.

Nautilus Biotechnology, Inc.
Nautilus Biotechnology logo
Country United States
Founded 2016
Industry Biotechnology
Sector Healthcare
Employees 167
CEO Sujal Patel

Contact Details

Address:
2701 Eastlake Avenue East
Seattle, Washington 98102
United States
Phone 206 333 2001
Website nautilus.bio

Stock Details

Ticker Symbol NAUT
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001808805
CUSIP Number 63909J108
ISIN Number US63909J1088
Employer ID 98-1541723
SIC Code 3826

Key Executives

Name Position
Sujal M. Patel Co-Founder, Chief Executive Officer, President, Secretary and Director
Dr. Parag Mallick Ph.D. Co-Founder, Chief Scientist and Director
Anna Mowry Chief Financial Officer and Treasurer
Matthew B. Murphy ESQ. General Counsel
Chris Blessington Vice President of Corporate Marketing and Communications
Kentaro Suzuki Chief Marketing Officer
Gwen E. Weld Chief People Officer
Nick A. Nelson Chief Business Officer and Senior Vice President of Business Development
Dr. Subra Sankar Ph.D. Senior Vice President of Product Development

Latest SEC Filings

Date Type Title
Nov 19, 2024 144 Filing
Nov 14, 2024 SC 13D/A [Amend] General statement of acquisition of beneficial ownership
Nov 12, 2024 144 Filing
Nov 8, 2024 144 Filing
Nov 7, 2024 144 Filing
Oct 29, 2024 10-Q Quarterly Report
Oct 29, 2024 8-K Current Report
Sep 23, 2024 144 Filing
Sep 17, 2024 144 Filing
Jul 30, 2024 10-Q Quarterly Report